Homepage Top Section2

With this financing round, the company’s total funding reached more than $25m. Small molecule drugs developed by the company specifically target viral proteins crucial to the polyomavirus life

Acromegaly is a serious disease which is generally caused by a benign pituitary adenoma. Paltusotine would be the first, once-daily, oral selective somatostatin receptor type 2 nonpeptide agonist

TO-208, known as VP-102 in the US and marketed under the brand name YCANTH, contains cantharidin as its active ingredient. A Phase III clinical trial was conducted in

This designation marks the beginning of the UK Innovative Licensing and Access Pathway (ILAP), which is designed to expedite the development and access of new medicines in the

This move grants Theratechnologies the ‘rights’ to potentially introduce treatments for familial chylomicronaemia syndrome (FCS), hereditary angioedema (HAE), and severe hypertriglyceridemia (sHTG) within the Canadian market. Under the

The single-asset focused partnership leverages Tubulis’ platforms, Tubutecan and Alco5, to create an ADC with stability and reduced off-target toxicity, addressing present treatment challenges. Under the agreement terms,

This designation is effective as of 27 November this year. Sparsentan was originally developed by Travere Therapeutics and was in-licensed to Renalys Pharma, which holds license for its

VELSIPITY already secured approvals in the European Union, the US, and other countries through Everest’s licensing partner, Pfizer. The acceptance was grounded on data from the ELEVATE UC

India has now become the third country to have access to this PD-1 inhibitor, following the US and China. The drug will be marketed under the brand name